KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Short term Debt (2016 - 2025)

Historic Short term Debt for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $1.8 billion.

  • Teva Pharmaceutical Industries' Short term Debt rose 218.98% to $1.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.8 billion, marking a year-over-year increase of 218.98%. This contributed to the annual value of $1.8 billion for FY2025, which is 218.98% up from last year.
  • According to the latest figures from Q4 2025, Teva Pharmaceutical Industries' Short term Debt is $1.8 billion, which was up 218.98% from $24.0 million recorded in Q3 2025.
  • Teva Pharmaceutical Industries' Short term Debt's 5-year high stood at $3.5 billion during Q2 2021, with a 5-year trough of $24.0 million in Q3 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' median Short term Debt value was $1.9 billion (recorded in 2023), while the average stood at $1.9 billion.
  • Its Short term Debt has fluctuated over the past 5 years, first skyrocketed by 19912.02% in 2024, then plummeted by 9906.98% in 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Short term Debt (Quarter) stood at $1.4 billion in 2021, then skyrocketed by 47.9% to $2.1 billion in 2022, then dropped by 20.72% to $1.7 billion in 2023, then grew by 6.52% to $1.8 billion in 2024, then grew by 2.19% to $1.8 billion in 2025.
  • Its Short term Debt was $1.8 billion in Q4 2025, compared to $24.0 million in Q3 2025 and $464.0 million in Q2 2025.